Business Wire - August 22, 2000

The legislation represents the latest U.S. effort in the long-term global fight against HIV/AIDS and its related threat of tuberculosis. This new initiative builds on the $1.4-billion already invested by the United States in international AIDS programs since the start of the epidemic.

"Last year, AIDS killed 2.8 million people world-wide," said Joel Schoenfeld, chairman of UNIVEC. "I praise our benevolence and compassion but criticize our complacency in adding to the epidemic proportions by not outlawing re-usable syringes, which every humanitarian agency acknowledges increases the risks of infection."

"We pour millions more into vaccination programs with re-usable syringes that could be improperly sterilized and later discarded to be used multi-times in the drug culture," said Schoenfeld. "It is, seemingly, obvious that we are also paying to spread infection, unless we also mandate universally auto-disable syringes."

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the company's Securities and Exchange filings under "Risk Factors," including risks relating to dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the company's proposed products (such as marketing, safety, regulatory, patent product liability, supply, competition and other risks).

--30--twt/ix*

CONTACT: UNIVEC Corporation, Farmingdale Joel Schoenfeld, 631/777-2000 UNIVEC@UNIVEC.com
000822
BW000804

Copyright © 2000 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .